Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Interest & Investment Income (2016 - 2021)

Sonoma Pharmaceuticals has reported Interest & Investment Income over the past 12 years, most recently at $2000.0 for Q1 2021.

  • For Q1 2021, Interest & Investment Income rose 102.99% year-over-year to $2000.0; the TTM value through Mar 2021 reached $15000.0, down 70.0%, while the annual FY2021 figure was $16000.0, 68.0% down from the prior year.
  • Interest & Investment Income for Q1 2021 was $2000.0 at Sonoma Pharmaceuticals, down from $3000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $173000.0 in Q1 2018 and troughed at -$67000.0 in Q1 2020.
  • A 5-year average of $31000.0 and a median of $33000.0 in 2019 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: surged 5200.0% in 2017 and later crashed 231.37% in 2020.
  • Year by year, Interest & Investment Income stood at $14000.0 in 2017, then surged by 164.29% to $37000.0 in 2018, then fell by 10.81% to $33000.0 in 2019, then crashed by 90.91% to $3000.0 in 2020, then crashed by 33.33% to $2000.0 in 2021.
  • Business Quant data shows Interest & Investment Income for SNOA at $2000.0 in Q1 2021, $3000.0 in Q4 2020, and $8000.0 in Q3 2020.